

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1. (currently amended) A hybrid ~~oligomer~~ oligonucleotide comprising a CRE sequence and a sequence that hybridizes to ~~the~~ a bcl-2 pre-mRNA or mRNA.
2. (currently amended) The hybrid ~~oligomer~~ oligonucleotide of Claim 1, wherein the sequence[[,]] which hybridizes to the bcl-2 pre-mRNA or mRNA[[,]] comprises at least 10 consecutive bases that are complementary to the bcl-2 pre-mRNA or mRNA.
3. (currently amended) The hybrid ~~oligomer~~ oligonucleotide of Claim 1, wherein the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA comprises 5'-TCTCCCAGCG-3' (SEQ ID NO:35).
4. (currently amended) The hybrid ~~oligomer~~ oligonucleotide of Claim 1, wherein the CRE sequence comprises 5'-TGACGTCA-3'.
5. (currently amended) The hybrid ~~oligomer~~ oligonucleotide of Claim 4, further comprising the sequence 5'-TCTCCCAGCG-3' (SEQ ID NO:35).
6. (currently amended) The hybrid ~~oligomer~~ oligonucleotide of Claim 1, wherein the CRE sequence is linked to the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA.
7. (currently amended) The hybrid ~~oligomer~~ oligonucleotide of Claim 6, wherein the CRE sequence comprises two or more CRE consensus sequences.
8. (currently amended) The hybrid ~~oligomer~~ oligonucleotide of Claim 7, wherein a first CRE consensus sequence is linked to a second CRE consensus sequence by one or more bases.

9. (withdrawn) A method of inhibiting the growth of cancer cells *in vitro* comprising contacting the cancer cells with a hybrid ~~oligomer~~ oligonucleotide comprising a CRE sequence and a sequence that hybridizes to ~~the~~ a bcl-2 pre-mRNA or mRNA.

10. (withdrawn) The method of Claim 9, wherein the sequence[[,]] which hybridizes to the bcl-2 pre-mRNA or mRNA[[,]] comprises at least 10 consecutive bases that are complementary to the bcl-2 pre-mRNA or mRNA.

11. (withdrawn) The method of Claim 9, wherein the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA comprises 5'-TCTCCCAGCG-3' (SEQ ID NO:35).

12. (withdrawn) The method of Claim 9, wherein the CRE sequence comprises 5'-TGACGTCA-3'.

13. (withdrawn) The method of Claim 12, wherein the hybrid ~~oligomer~~ oligonucleotide further comprises the sequence 5'-TCTCCCAGCG-3' (SEQ ID NO:35).

14. (withdrawn) The method of Claim 9, wherein the CRE sequence is linked to the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA.

15. (withdrawn) The method of Claim 14, wherein the CRE sequence comprises two or more CRE consensus sequences.

16. (withdrawn) The method of Claim 15, wherein a first CRE consensus sequence is linked to a second CRE consensus sequence by one or more bases.

17. (withdrawn) The method of Claim 9, further comprising contacting the cancer cells with a bcl-2 antisense ~~oligomer~~ oligonucleotide.

18. (withdrawn) The method of Claim 9, further comprising contacting the cancer cells with a CRE decoy ~~oligomer~~ oligonucleotide.

19. (withdrawn) The method of Claim 9, further comprising contacting the cancer cells with a bcl-2 antisense ~~oligomer~~ oligonucleotide and a CRE decoy ~~oligomer~~ oligonucleotide.

20. (withdrawn) The method of Claim 9, further comprising contacting the cancer cells with one or more cancer therapeutic agents.

21. (withdrawn) A method of treating or preventing cancer in a human comprising administering to said human, in which such treatment or prevention is desired, a hybrid ~~oligomer~~ oligonucleotide comprising a CRE sequence and a sequence that hybridizes to the bcl-2 pre-mRNA or mRNA.

22. (withdrawn) The method of Claim 21, wherein the sequence, which hybridizes to the bcl-2 pre-mRNA or mRNA comprises at least 10 consecutive bases that are complementary to the bcl-2 pre-mRNA or mRNA.

23. (withdrawn) The method of Claim 21, wherein the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA comprises 5'-TCTCCCAGCG-3'(SEQ ID NO:35).

24. (withdrawn) The method of Claim 21, wherein the CRE sequence comprises 5'-TGACGTCA-3'.

25. (withdrawn) The method of Claim 24, wherein the hybrid ~~oligomer~~ oligonucleotide further comprises the sequence 5'-TCTCCCAGCG-3' (SEQ ID NO:35).

26. (withdrawn) The method of Claim 21, wherein the CRE sequence is linked to the sequence that hybridizes to the bcl-2 pre-mRNA or mRNA.

27. (withdrawn) The method of Claim 26, wherein the CRE sequence comprises two or more CRE consensus sequences.

28. (withdrawn) The method of Claim 27, wherein a first CRE consensus sequence is

linked to a second CRE consensus sequence by one or more bases.

29. (withdrawn) The method of Claim 21, further comprising administering a bcl-2 antisense ~~oligomer~~ oligonucleotide.

30. (withdrawn) The method of Claim 21, further comprising administering a CRE decoy ~~oligomer~~ oligonucleotide.

31. (withdrawn) The method of Claim 21, further comprising administering a bcl-2 antisense ~~oligomer~~ oligonucleotide and a CRE decoy ~~oligomer~~ oligonucleotide.

32. (withdrawn) The method of Claim 21, further comprising administering one or more cancer therapeutic agents.

33. (withdrawn) The method of Claim 32, wherein administration of the cancer therapeutic agent follows administration of the bcl-2 antisense ~~oligomer~~ oligonucleotide and the CRE decoy ~~oligomer~~ oligonucleotide.

34. (withdrawn) The method of Claim 32, wherein administration of the cancer therapeutic agent precedes administration of the bcl-2 antisense ~~oligomer~~ oligonucleotide and the CRE decoy ~~oligomer~~ oligonucleotide.

35. (withdrawn) The method of Claim 32, wherein the cancer therapeutic agent is administered concurrently with the bcl-2 antisense ~~oligomer~~ oligonucleotide and the CRE decoy ~~oligomer~~ oligonucleotide.

36. (withdrawn) The method of Claim 32, wherein said cancer therapeutic agent is a chemoagent, radiotherapeutic, immunotherapeutic, cancer vaccine, anti-angiogenic agent, cytokine, gene therapeutic, or hormonal agent.

37. (withdrawn) The method of Claim 32, wherein said cancer therapeutic agent is a

chemoagent, and wherein said chemoagent is dacarbazine, docetaxel, paclitaxel, cisplatin, 5-fluorouracil, doxorubicin, etoposide, cyclophosphamide, fludarabine, irinotecan, or cytosine arabinoside (Ara-C).

38. (withdrawn) The method of Claim 32, wherein said cancer therapeutic agent is administered at a reduced dose.

39. (withdrawn) The method of Claim 21, wherein said administration is by oral, intravenous infusion, subcutaneous injection, intramuscular injection, topical, depo injection, implantation, time-release mode, intracavitary, intranasal, inhalation, intratumor, or intraocular administration.

40. (withdrawn) The method of Claim 21, wherein the hybrid oligomer oligonucleotide is administered for a period consisting of 2 to 13 days.

41. (withdrawn) The method of Claim 21, wherein the hybrid oligomer oligonucleotide is administered for a period consists consisting of 14 to 28 days.

42. (withdrawn) The method of Claim 21, comprising administering 0.01 to 10 mg/kg/day of a the hybrid oligonucleotide oligomer.

43. (withdrawn) The method of Claim 21, comprising administering 10 to 50mg/kg/day of a the hybrid oligonucleotide oligomer.

44. (withdrawn) A method of inhibiting the growth of cancer cells *in vitro* comprising contacting the cancer cells with a bcl-2 antisense oligonucleotide oligomer and a CRE decoy oligonucleotide oligomer.

45. (withdrawn) The method of Claim 44, wherein the bcl-2 antisense oligonucleotide oligomer comprises the sequence 5'-TCTCCCAGCG-3' (SEQ ID NO:35).

46. (withdrawn) The method of Claim 44, wherein the CRE decoy oligonucleotide oligomer comprises the sequence 5-TGACGTCA-3'.

47. (withdrawn) The method of Claim 44, wherein the CRE decoy oligonucleotide oligomer comprises two or more CRE consensus sequences.

48. (withdrawn) The method of Claim 44, wherein a first CRE consensus sequence is linked to a second CRE consensus sequence by one or more bases.

49. (withdrawn) The method of Claim 44, further contacting the cancer cells with one or more cancer therapeutic agents.

50. (withdrawn) A method of treating or preventing cancer in a human comprising administering to said human, in which such treatment or prevention is desired, a bcl-2 antisense oligonucleotide oligomer and a CRE decoy oligonucleotide oligomer.

51. (withdrawn) The method of Claim 50, wherein the bcl-2 antisense oligonucleotide oligomer comprises the sequence 5-TCTCCCAGCG-3' (SEQ ID NO:35).

52. (withdrawn) The method of Claim 50, wherein the CRE decoy oligonucleotide oligomer comprises the sequence 5-TGACGTCA-3'.

53. (withdrawn) The method of Claim 50, wherein the CRE decoy oligonucleotide oligomer comprises two or more CRE consensus sequences.

54. (withdrawn) The method of Claim 50, wherein a first CRE consensus sequence is linked to a second CRE consensus sequence by one or more bases.

55. (withdrawn) The method of Claim 50, further comprising administering one or more cancer therapeutic agents.

56. (withdrawn) The method of Claim 55, wherein administration of the cancer

therapeutic agent follows administration of the bcl-2 antisense oligonucleotide oligomer and the CRE decoy oligonucleotide oligomer.

57. (withdrawn) The method of Claim 55, wherein administration of the cancer therapeutic agent precedes administration of the bcl-2 antisense oligonucleotide oligomer and the CRE decoy oligonucleotide oligomer.

58. (withdrawn) The method of Claim 55, wherein the cancer therapeutic agent is administered concurrently with the bcl-2 antisense oligonucleotide oligomer and the CRE decoy oligonucleotide oligomer.

59. (withdrawn) The method of Claim 55, wherein said cancer therapeutic agent is a chemoagent, radiotherapeutic, immunotherapeutic, cancer vaccine, anti-angiogenic agent, cytokine, gene therapeutic, or hormonal agent.

60. (withdrawn) The method of Claim 55, wherein said cancer therapeutic agent is a chemoagent, and wherein said chemoagent is dacarbazine, docetaxel, paclitaxel, cisplatin, 5-fluorouracil, doxorubicin, etoposide, cyclophosphamide, fludarabine, irinotecan or cytosine arabinoside (Ara-C).

61. (withdrawn) The method of Claim 55, wherein said cancer therapeutic agent is administered at a reduced dose.

62. (withdrawn) The method of Claim 50, wherein said administration is by oral, intravenous infusion, subcutaneous injection, intramuscular injection, topical, depo injection, implantation, time-release mode, intracavitory, intranasal, inhalation, intratumor, or intraocular administration.

63. (withdrawn) The method of Claim 50, wherein the hybrid oligonucleotide oligomer is administered for a period consisting of 2 to 13 days.

64. (withdrawn) The method of Claim 50, wherein the hybrid oligonucleotide oligomer is administered for a period consisting of 14 to 28 days.

65. (withdrawn) The method of Claim 50, comprising administering 0.01 to 10 mg/kg/day of a the hybrid oligonucleotide oligomer.

66. (withdrawn) The method of Claim 50, comprising administering 10 to 50mg/kg/day of a the hybrid oligonucleotide oligomer.

67. (currently amended) A pharmaceutical composition comprising a hybrid oligonucleotide oligomer comprising a CRE sequence and a sequence that hybridizes to a the bcl-2 pre-mRNA or mRNA; and a pharmaceutically acceptable carrier.

68. (currently amended) The pharmaceutical composition of Claim 67 further comprising a bcl-2 antisense oligonucleotide oligomer.

69. (currently amended) The pharmaceutical composition of Claim 67 further comprising a CRE decoy oligonucleotide oligomer.

70. (currently amended) The pharmaceutical composition of Claim 67 further comprising a bcl-2 antisense oligonucleotide oligomer and a CRE decoy oligonucleotide oligomer.

71. (currently amended) A pharmaceutical composition comprising a CRE decoy oligonucleotide oligomer and a bcl-2 antisense oligonucleotide oligomer; and a pharmaceutically acceptable carrier.